Kairos Pharma to Present at H.C. Wainwright Global Investment Conference
Kairos Pharma's participation in the prestigious H.C. Wainwright conference provides crucial visibility for its innovative cancer therapeutic ENV105, which addresses significant unmet medical needs in drug-resistant cancers.
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announced that CEO and Chairman John Yu, MD, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference will be held September 8-10, 2025, at the Lotte New York Palace Hotel in New York.
The company's presentation at this prominent investment conference represents a significant opportunity to showcase its lead candidate, ENV105, an antibody targeting CD105 - a protein identified as a key driver of resistance to various cancer treatments. This appearance matters because it provides visibility to potential investors and partners during a critical development phase for the company's pipeline.
Kairos Pharma utilizes structural biology to overcome drug resistance and immune suppression in cancer. Elevation of CD105 in response to standard therapy results in resistance and disease relapse, making ENV105's mechanism of action particularly important for addressing treatment failures in oncology. The antibody aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.
Currently, ENV105 is advancing through clinical trials with a Phase 2 study for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer. These trials address significant unmet medical needs in oncology, where drug resistance remains a major challenge in patient care. The company's progress can be tracked through its newsroom available at https://ibn.fm/KAPA.
The H.C. Wainwright conference serves as an important platform for emerging biotechnology companies to connect with the investment community. For Kairos Pharma, this presentation timing coincides with ongoing clinical development, potentially influencing investor confidence and future funding opportunities. The full press release detailing the conference participation is available at https://ibn.fm/mdybH.
This conference appearance underscores the growing interest in novel approaches to cancer treatment, particularly those addressing drug resistance mechanisms. As the company continues to develop ENV105, visibility at major investment conferences becomes increasingly important for securing the resources needed to advance clinical programs and ultimately bring new treatment options to patients facing drug-resistant cancers.